First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

MELBOURNE, Australia, Nov. 21, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first pati...

Related Keywords

Australia ,Japan ,United States ,United Kingdom ,Belgium ,Austria ,Melbourne ,Victoria ,Canada ,Switzerland ,Australian ,Ordensklinikum Linz ,Kyahn Williamson ,Colin Hayward ,Barmherzige Schwestern ,Josef Pichler ,Christian Behrenbruch ,Telix Pharmaceuticals ,Linkedin ,Kepler University Hospital ,Kepler University Hospital In Linz ,Drug Administration ,Australian Securities Exchange ,Australian Therapeutic Goods Administration ,Corporate Communications ,Telix Pharmaceuticals Limited ,Health Canada ,Professor Josef Pichler ,Principal Investigator ,Chief Medical Officer ,Managing Director ,Group Chief Executive ,